ICU Medical Inc ICUI
No target with a reported result yet
Releases of the last 3 yearsThe numbers ICUI said it expected, in its earnings releases, next to what it then reported for the same period.
Target by target
Each target, with the sentence it came from · release and 10-Q or 10-K
| Target | What the company said | Reported | Result | |
|---|---|---|---|---|
| EBITDA (company-defined) Fiscal 2026 |
Given $400.00M to $430.00M release Feb 19, 2026
Raised $415.00M to $435.00M release Nov 5, 2026
|
– | No standard number | |
The company's wordsFor the fiscal year 2026, the Company expects adjusted EBITDA to be in the range of $400 million to $430 million, and adjusted EPS to be in the range of $7.75 to $8.45. release Feb 19, 2026 The Company's previously provided full year 2026 guidance of Adjusted EBITDA remains estimated to be in the range of $415 million to $435 million and adjusted diluted earnings per share to be in the range of $8.60 to $9.00. release Nov 5, 2026 | ||||
| Net income Fiscal 2026 |
Given $73.00M to $83.00M release Nov 5, 2026
|
– | Not reported yet | |
The company's wordsThe Company's previously provided full year GAAP net income remains estimated to be in the range of $73 million to $83 million and GAAP diluted earnings per share to be in the range of $2.89 to $3.29. release Nov 5, 2026 | ||||
| Diluted EPS (company-defined) Fiscal 2026 |
Given $7.75 to $8.45 release Feb 19, 2026
Raised $8.60 to $9.00 release Nov 5, 2026
|
– | No standard number | |
The company's wordsFiscal Year 2026 Guidance … For the fiscal year 2026, the Company expects adjusted EBITDA to be in the range of $400 million to $430 million, and adjusted EPS to be in the range of $7.75 to $8.45. release Feb 19, 2026 The Company's previously provided full year 2026 guidance of Adjusted EBITDA remains estimated to be in the range of $415 million to $435 million and adjusted diluted earnings per share to be in the range of $8.60 to $9.00. release Nov 5, 2026 | ||||
| Diluted EPS Fiscal 2026 |
Given $2.89 to $3.29 release Nov 5, 2026
|
– | Not reported yet | |
The company's wordsThe Company's previously provided full year GAAP net income remains estimated to be in the range of $73 million to $83 million and GAAP diluted earnings per share to be in the range of $2.89 to $3.29. release Nov 5, 2026 | ||||
| EBITDA (company-defined) Fiscal 2025 (ended Dec 31, 2025) |
Given $395.00M to $425.00M release Feb 27, 2025
|
– | No standard number | |
The company's wordsFor the fiscal year 2025, excluding the potential impact from the Company's previously announced IV Solutions joint venture transaction, the Company expects adjusted EBITDA to be in the range of $395 million to $425 million, and adjusted EPS to be in the range of $6.55 to $7.25. release Feb 27, 2025 | ||||
| Diluted EPS (company-defined) Fiscal 2025 (ended Dec 31, 2025) |
Given $6.55 to $7.25 release Feb 27, 2025
|
– | No standard number | |
The company's wordsFiscal Year 2025 Guidance … For the fiscal year 2025, excluding the potential impact from the Company's previously announced IV Solutions joint venture transaction, the Company expects adjusted EBITDA to be in the range of $395 million to $425 million, and adjusted EPS to be in the range of $6.55 to $7.25. release Feb 27, 2025 | ||||
| EBITDA (company-defined) Fiscal 2024 (ended Dec 31, 2024) |
Given $330.00M to $370.00M release Feb 27, 2024
|
– | No standard number | |
The company's wordsFor the Fiscal Year 2024, the Company expects adjusted EBITDA to be in the range of $330 million to $370 million, and adjusted diluted EPS to be in the range of $4.40 to $5.10. release Feb 27, 2024 | ||||
| Diluted EPS (company-defined) Fiscal 2024 (ended Dec 31, 2024) |
Given $4.40 to $5.10 release Feb 27, 2024
|
– | No standard number | |
The company's wordsFiscal Year 2024 Guidance … For the Fiscal Year 2024, the Company expects adjusted EBITDA to be in the range of $330 million to $370 million, and adjusted diluted EPS to be in the range of $4.40 to $5.10. release Feb 27, 2024 | ||||
Targets are read from the sentences of the EX-99 exhibits of 8-K item 2.02 filings (12 releases since 2024-02-27), without AI; in outlook tables only the first column is read. The result compares the reported number with the last range given before the period was reported. Results come from SEC's XBRL company facts, as first reported. A company's target can use its own definition (META's capital expenditures include finance lease payments, for example), so read the quote.
Sources
The outlook sentences of each earnings release (8-K item 2.02, exhibit 99), read without AI; results from SEC's XBRL company facts, as first reported.
Also
Earnings releases: each release in full.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ICUI/export.csv") into a cell.